Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795227B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2022 |
| Grant date | Oct 24, 2023 |
| Priority date | — |
| Expiry date | Mar 21, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 ε. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.